Bernini G P, Moretti A, Borgioli M, Bardini M, Miccoli P, Berti P, Basolo F, Faviana P, Birindelli R, Salvetti A
Department of Internal Medicine, Univeristy of Pisa, Pisa, Italy.
J Endocrinol Invest. 2004 Oct;27(9):821-5. doi: 10.1007/BF03346275.
Adrenal adenomas frequently arise from cortical islets in the medulla, and these islets seem to present a greater risk for pathological growth than cortical cells within the adrenal cortex. Chromogranin A (CgA), a glycoprotein co-stored in secreting granules and co-released with resident hormones of chromaffin cells, behaves as a prohormone, generating several biologically active peptides capable of influencing growth, morphogenesis and progression of endocrine tumors. The aim of our study was to investigate whether chromaffin cells may be involved in the development and growth of adrenocortical adenomas. We enrolled 19 patients (12 females and 7 males, mean+/-SD age 54.9+/-11.2 yr, age range 34-75 yr) with incidental, non-functioning, benign adrenocortical adenomas, and measured circulating levels of CgA, catecholamines and creatinine before and 2 months after surgery. Plasma CgA was evaluated by immunoradiometric assay. Testing for CgA immunoreactivity in the removed tissues was performed by immunohistochemical analysis. Mean plasma CgA did not significantly change following surgery (before 73.7+/-15.2 ng/ml; after 68.9+/-14.8 ng/ml). Individual CgA values indicated that 4 patients had plasma CgA levels above our cut-off of normality. After mass removal, CgA further increased in 2 cases, decreased in 1 and normalized in 1. No variation in CgA levels was found in the other patients. No correlation was observed between CgA and the variables measured, except between CgA and plasma creatinine (r=0.472, p<0.05). Histopathological evaluation revealed adrenocortical adenomas in all cases and immunohistochemical analysis detected no CgA immunoreactivity in any specimen. Our results show that in human adrenocortical adenomas CgA is not expressed and that removal of the mass does not modify plasma CgA levels. For these reasons the endocrine involvement of local CgA in adrenocortical tumorigenesis is unlikely.
肾上腺腺瘤常起源于髓质中的皮质小岛,相较于肾上腺皮质内的皮质细胞,这些小岛似乎更易发生病理性生长。嗜铬粒蛋白A(CgA)是一种与分泌颗粒共同储存并与嗜铬细胞的固有激素共同释放的糖蛋白,其作用类似前激素,可产生多种能够影响内分泌肿瘤生长、形态发生和进展的生物活性肽。我们研究的目的是调查嗜铬细胞是否可能参与肾上腺皮质腺瘤的发生和生长。我们纳入了19例患有偶然发现的、无功能的良性肾上腺皮质腺瘤的患者(12例女性和7例男性,平均±标准差年龄54.9±11.2岁,年龄范围34 - 75岁),并在手术前及术后2个月测量了循环中的CgA、儿茶酚胺和肌酐水平。血浆CgA通过免疫放射分析进行评估。通过免疫组织化学分析对切除组织进行CgA免疫反应性检测。术后平均血浆CgA无显著变化(术前73.7±15.2 ng/ml;术后68.9±14.8 ng/ml)。个体CgA值表明4例患者的血浆CgA水平高于我们设定的正常临界值。肿块切除后,2例患者的CgA进一步升高,1例降低,1例恢复正常。其他患者未发现CgA水平有变化。除了CgA与血浆肌酐之间(r = 0.472,p < 0.05),未观察到CgA与所测变量之间存在相关性。组织病理学评估显示所有病例均为肾上腺皮质腺瘤,免疫组织化学分析在任何标本中均未检测到CgA免疫反应性。我们的结果表明,在人类肾上腺皮质腺瘤中CgA不表达,且肿块切除不会改变血浆CgA水平。基于这些原因,局部CgA参与肾上腺皮质肿瘤发生的内分泌机制不太可能。